Finding the right #compounds for the right #diseases is a key challenge in #DrugRepositioning. Delta4’s Hyper-C platform starts with disease biology to identify promising therapeutic opportunities and provides mechanistic rationales to support development decisions. Read more: delta4.ai/services/

Many diseases require more than a single #therapeutic approach. With the support of #Combo-C, we identify and evaluate promising #DrugCombinations, providing the biological rationale behind each prediction—helping pharma prioritize candidates before the lab. Explore: delta4.ai/services/ #Delta4

Sjögren's syndrome is often described as a disease of dry eyes and dry mouth. But the reality is far more complex. Around 90% of people diagnosed with Sjögren's are women, and many symptoms overlap with perimenopause and menopause, contributing to delayed recognition and diagnosis. #SjogrensDay

#SyntheticLethality is not only about new targets — it’s about treating the right patients in the right way. With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more: 🔗 delta4.ai/synthetic-lethality

Chronic diseases aren’t just “organ problems.” Nearly 1 in 3 adults lives with multiple chronic conditions, driven by shared systemic processes. A systems biology view helps us find new levers for resilience and shows that biology is not static, but open to positive influence. #ChronicDiseaseDay

#CKD research is moving fast, but translation into practice still lags. The KidneyHealth #COST Action CA25128 (starting Sept) builds a Europe-wide network to bridge that gap. D4's Computational Biology Lead represents Austria on the Mgmt Committee. Join the effort! www.cost.eu/actions/CA25...

#DISCOVER-ME has officially launched! The first #HorizonEurope project dedicated to ME/CFS brings together 20 international partner institutions & leading experts in ME/CFS and Post-Acute Infection Syndromes (#PAIS). One of the goals: pave the way for targeted treatment strategies. #MECFS

Diseases are rarely driven by a single pathway. Drugs rarely act on a single mechanism. By integrating diverse biological data into a unified framework, the Hyper-C platform helps identify connections that may otherwise remain hidden. Explore: delta4.ai/hyper-c/ #DrugDiscovery #AI #SystemsBiology

#Synthetic lethality is a promising concept in precision oncology, but discovery remains the bottleneck. With ~20,000 genes, the number of possible interactions is enormous. Most remain unmapped, but computational approaches can help narrow the space. ➡️https://delta4.ai/synthetic-lethality #Oncology

Most people know their blood type because it matters for transfusions during emergencies. But ABO blood groups influence clotting, interactions with pathogens, and even susceptibility to certain diseases. Your blood type may modify risk—but it doesn't determine your future. #WorldBloodDonorDay

Austria's life science ecosystem continues to grow and innovate. We're excited to join Austrian Life Science Day on June 16th to connect with researchers, biotech innovators, and industry partners from across the community. Let's meet there! #AustrianLifeScienceDay #LifeSciences #Biotech

MS is increasingly understood as more than an autoimmune disease. 💡 Neuroinflammation, glial cells, neurodegeneration, and tissue repair interact in highly complex ways. Progress will come from understanding these systems and their interplay. #WorldMSDay #MultipleSclerosis #Neuroinflammation

The FDA is encouraging drug repurposing—finding new uses for existing drugs in areas of unmet need. At Delta4, we extend this to drug combinations, aiming to identify synergistic, multi-target strategies for complex diseases. #DrugRepurposing #SystemsBiology #PrecisionMedicine

#Delta4's Enrico presented his poster at the #YSA Symposium 2026 at the Medical University of Vienna. His work on systems-biological modeling of the #AKI-to-#CKD transition was selected for Session V (Regeneration & Transplantation) and sparked lively scientific discussion. #TranslationalResearch

ME/CFS is complex, multi-system, and still poorly understood. Multiple ongoing research efforts aim to decode its biology, enabling better diagnosis and targeted treatments. Progress starts with understanding complex disease, and AI-supported target discovery is one piece of that puzzle. #MECFS

Ovarian cancer is not just about earlier detection—it’s about complex biology. Heterogeneity and resistance limit one-size-fits-all treatment. Progress will come from understanding mechanisms, not just identifying disease. #WorldOvarianCancerDay #Oncology #PrecisionMedicine

Stress isn’t just lifestyle—it triggers real biological cascades: #inflammation, #hormonal imbalance, #tissue damage. Over time, this drives disease. Managing stress is a long-term investment in your bodily health. #BeTheChange #SystemsBiology #Relax #StressAwareness #ChronicStress

Diseases like #ADPKD and #FSGS are driven by complex, interconnected biological networks. What if the key to better therapies lies not in one target — but in understanding the system? At Delta4, we advocate for a shift towards network-based approaches in #drugDiscovery. #systemsbiology #techbio

Delta4 will be represented at #Bio€quity Europe in Prague by Josef Thalmann, who will be on-site for investor meetings and collaboration discussions in the field of data-driven drug repositioning and indication expansion. If you plan to attend, feel free to reach out and schedule a conversation!

WORLD #LIVER DAY: Liver safety and liver disease aren’t separate problems. Cases like #Ontozry show risks still emerge post-approval, while PBC/PSC reflect immune-driven damage. Different triggers—same system under stress. Read more on #Delta4's work in #PBC/#PSC: delta4.ai/development-...

In proof-of-concept clinical trials, mechanism matters more than magnitude. Targeted #biomarkers and multi-#omics approaches help researchers to: 🧬Confirm #target engagement, 🧬Identify #responder subgroups, 🧬Reduce noise in small #cohorts. Read more: delta4.ai/proof-of-con...

💡 #Collagen fragments in urine can predict #mortality across ICU and non-ICU populations (#Proteomics). Not a single biomarker, but a systemic readout of #tissue integrity and structural change. Read more on this non-invasive signal in the following study: doi.org/10.1002/pmic... #BiomarkerResearch

At Delta4, our commitment to the rare disease community is grounded in both compassion and rigorous data science. Together, we are transforming awareness into meaningful action—supporting innovation and hope for everyone affected by rare diseases. 💙💪 #Delta4 #RareDisease #Innovation

Better health won’t come from fitting patients into models, but from understanding when they don’t fit. AI is great at finding patterns — but biology doesn’t always follow them. Rare diseases, individual variability, and context need smarter approaches. #WorldHealthDay #TogetherForScience

💡 Most drug discovery tools look at biology in segments. Hyper-C is built to see diseases and drugs play out across systems. Explore Hyper-C's core components at 📍 delta4.ai/hyper-c #DrugDiscovery #SystemsBiology #Biotech #TargetDiscovery #BiomarkerID #indicationExpansion

Great discussions at the #PICKED webseminars 👏 9 DC presentations, strong supervisor feedback, and real cross-project exchange. More: www.projectpicked.eu/news-and-eve... Next up: Tallinn (15–16 Sept) #HorizonEU #MSCA #RareDiseases

#PerMediK’s 8th Meeting marked the start of its final year. A strong network driving collaboration in personalised medicine for #CKD — now facing the key task of aligning scientific exchange with real-world impact. Great to have Paul & Kinga from Delta4 on site, exchanging ideas and experience.

💡What if the next #KidneyDisease therapy is already in your pipeline? By leveraging in-silico modeling and network biology, we can: ✔ Identify new targets ✔ Reveal biomarkers ✔ Expand indications for existing assets ✔ De-risk development early. Let's rethink kidney disease as an #opportunity.

Kidney disease highlights both the promise and the challenge of PoC clinical trials. Slow disease progression and heterogeneous biology make traditional endpoints impractical in early studies. 🧬Explore more: delta4.ai/proof-of-con...

🌍 #Kidney disease often starts quietly — sometimes with small, seemingly unrelated changes in routine lab results. We believe that understanding connections across pathways and systems is key to uncovering new therapeutic strategies. Let's look beyond individual data points & find new approaches.